% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kronenberg:11439,
      author       = {Kronenberg, T.},
      title        = {{E}rstellung einer {I}nput-{O}utput-{T}abelle für
                      {M}ecklenburg-{V}orpommern},
      journal      = {Wirtschafts- und sozialstatistisches Archiv},
      volume       = {4},
      issn         = {1863-8155},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {PreJuSER-11439},
      pages        = {223 - 248},
      year         = {2010},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {The IRESSA Survival Evaluation in Lung Cancer (ISEL) phase
                      III study compared the efficacy of gefitinib (IRESSA) versus
                      placebo in patients with refractory advanced non-small cell
                      lung cancer (NSCLC). Although a statistically significant
                      difference in survival was not seen between gefitinib and
                      placebo in the overall ISEL population, preplanned subset
                      analyses demonstrated a significant survival benefit in
                      patients who had never smoked and in patients of Asian
                      origin.In ISEL, 1692 patients who were refractory to or
                      intolerant of their latest chemotherapy were randomized to
                      receive either gefitinib (250 mg/day) or placebo, plus best
                      supportive care. Preplanned subgroup analyses included an
                      assessment of patients who were of Asian origin (n =
                      342).Two hundred thirty-five patients of Asian origin
                      received gefitinib, and 107 received placebo. In these
                      patients, treatment with gefitinib significantly improved
                      survival compared with placebo (hazard ratio [HR], 0.66;
                      $95\%$ confidence interval [CI], 0.48, 0.91; p = 0.010;
                      median survival, 9.5 versus 5.5 months). Patients of Asian
                      origin also experienced statistically significant
                      improvements in time to treatment failure with gefitinib
                      compared with placebo (HR, 0.69; $95\%$ CI, 0.52, 0.91; p =
                      0.0084; 4.4 versus 2.2 months), and objective response rates
                      were higher with gefitinib than with placebo (12 versus
                      $2\%).$ Gefitinib was generally well tolerated in patients
                      of Asian origin, with rash and diarrhea being the most
                      common adverse events. No unexpected adverse events were
                      observed.Treatment with gefitinib was associated with a
                      significant improvement in survival in a subgroup of
                      patients of Asian origin with previously treated refractory
                      advanced NSCLC.},
      keywords     = {Adult / Aged / Aged, 80 and over / Antineoplastic Agents:
                      adverse effects / Antineoplastic Agents: therapeutic use /
                      Asian Continental Ancestry Group / Carcinoma, Non-Small-Cell
                      Lung: drug therapy / Carcinoma, Non-Small-Cell Lung:
                      ethnology / Carcinoma, Non-Small-Cell Lung: mortality /
                      Double-Blind Method / Female / Humans / Lung Neoplasms: drug
                      therapy / Lung Neoplasms: ethnology / Lung Neoplasms:
                      mortality / Male / Middle Aged / Protein Kinase Inhibitors:
                      adverse effects / Protein Kinase Inhibitors: therapeutic use
                      / Quinazolines: adverse effects / Quinazolines: therapeutic
                      use / Receptor, Epidermal Growth Factor: antagonists $\&$
                      inhibitors / Survival Rate / Antineoplastic Agents (NLM
                      Chemicals) / Protein Kinase Inhibitors (NLM Chemicals) /
                      Quinazolines (NLM Chemicals) / gefitinib (NLM Chemicals) /
                      Receptor, Epidermal Growth Factor (NLM Chemicals)},
      cin          = {IEF-STE},
      ddc          = {310},
      cid          = {I:(DE-Juel1)VDB815},
      pnm          = {Nachhaltige Entwicklung und Technik},
      pid          = {G:(DE-Juel1)FUEK408},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:17409969},
      doi          = {10.1007/s11943-010-0084-9},
      url          = {https://juser.fz-juelich.de/record/11439},
}